News & Press Releases
Ranbaxy Whistleblower Reveals How He Exposed Massive Pharmaceutical Fraud in a CBS News Report
Correspondent John Miller interviews Ranbaxy whistleblower Dinesh Thakur represented by Washington D.C. Attorneys Andrew Beato and Bob Muse
November 6, 2013
In this CBS NEWS Report, Dinesh Thakur, former Ranbaxy Director and Global Head, Research Information & Portfolio Management, explains why he became a whistleblower, exposing massive fraud and dubious manufacturing practices by this generic pharmaceutical giant.
With the assistance of his counsel Andrew M. Beato and Bob Muse of Stein Mitchell Muse Cipollone & Beato LLP in Washington, DC, Mr. Thakur filed a whistleblower lawsuit in 2007 under the FCA detailing Ranbaxy’s violations.
In May 2013, Ranbaxy agreed to pay $500 million to the United States and individual States to resolve allegations by Mr. Thakur that Ranbaxy falsified drug data and systemically violated Current Good Manufacturing and Laboratory Practices resulting in substandard and unapproved drugs. This groundbreaking settlement is the largest of its kind against a generic drug manufacturer under the qui tam provisions of the False Claims Act (“FCA”).
More CBS News coverage about the Ranbaxy pharmaceutical fraud: Whistleblower reveals how drug company faked results